The Adaptive Complexity of Cancer

被引:25
作者
Derbal, Youcef [1 ]
机构
[1] Ryerson Univ, Ted Rogers Sch Informat Technol Management, Toronto, ON, Canada
关键词
DNA-DAMAGE RESPONSE; SUPPRESSOR-CELLS; TUMOR MICROENVIRONMENT; T-CELLS; THERAPEUTIC RESISTANCE; IMMUNE SUPPRESSION; ENERGY SENSOR; INFLAMMATION; METABOLISM; LACTATE;
D O I
10.1155/2018/5837235
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cancer treatment options are expanding to the benefit of significant segments of patients. However, their therapeutic power is not equally realized for all cancer patients due to drug toxicity and disease resistance. Overcoming these therapeutic challenges would require a better understanding of the adaptive survival mechanisms of cancer. In this respect, an integrated view of the disease as a complex adaptive system is proposed as a framework to explain the dynamic coupling between the various drivers underlying tumor growth and cancer resistance to therapy. In light of this system view of cancer, the immune system is in principal the most appropriate and naturally available therapeutic instrument that can thwart the adaptive survival mechanisms of cancer. In this respect, new cancer therapies should aim at restoring immunosurveillance by priming the induction of an effective immune response through a judicious targeting of immunosuppression, inflammation, and the tumor nutritional lifeline extended by the tumor microenvironment.
引用
收藏
页数:14
相关论文
共 141 条
[1]   Combinatorial drug therapy for cancer in the post-genomic era [J].
Al-Lazikani, Bissan ;
Banerji, Udai ;
Workman, Paul .
NATURE BIOTECHNOLOGY, 2012, 30 (07) :679-691
[2]   CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement [J].
Amelio, Antonio L. ;
Fallahi, Mohammad ;
Schaub, Franz X. ;
Zhang, Min ;
Lawani, Mariam B. ;
Alperstein, Adam S. ;
Southern, Mark R. ;
Young, Brandon M. ;
Wu, Lizi ;
Zajac-Kaye, Maria ;
Kaye, Frederic J. ;
Cleveland, John L. ;
Conkright, Michael D. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (32) :E3260-E3268
[3]  
Ananieva Elitsa, 2015, World J Biol Chem, V6, P281, DOI 10.4331/wjbc.v6.i4.281
[4]   Rationalizing combination therapies [J].
不详 .
NATURE MEDICINE, 2017, 23 (10) :1113-1113
[5]  
[Anonymous], INT J BREAST CANC
[6]  
[Anonymous], 2020, CANC FACTS FIGURES 2
[7]   Immunity, inflammation and cancer: a leading role for adenosine [J].
Antonioli, Luca ;
Blandizzi, Corrado ;
Pacher, Pal ;
Hasko, Gyoergy .
NATURE REVIEWS CANCER, 2013, 13 (12) :842-857
[8]   CD39 and CD73 in immunity and inflammation [J].
Antonioli, Luca ;
Pacher, Pal ;
Vizi, E. Sylvester ;
Hasko, Gyoergy .
TRENDS IN MOLECULAR MEDICINE, 2013, 19 (06) :355-367
[9]   Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer [J].
Ballinger, Tarah J. ;
Meier, Jason B. ;
Jansen, Valerie M. .
FRONTIERS IN ONCOLOGY, 2018, 8
[10]  
Barker A., 2015, P NCRI CANC C 2015 L